OT: Upcoming Webinar: Unraveling the Secrets of the Epigenome
Posted: Mon Apr 08, 2013 7:06 pm
for those interested in epigenetics, very mainstream presentation of ongoing research.
free webinar
t
From: The Scientist Magazine
Sent: Monday, April 08, 2013 10:36 AM
To: tamarque@earthlink.net
Subject: Upcoming Webinar: Unraveling the Secrets of the Epigenome
Unraveling the Secrets of the Epigenome
________________________________
FREE Webinar — Thursday April 18, 2013
2:30-4:00 p.m. Eastern Time
Click here to register now!
While the human genome continues to intrigue researchers with the complexities embedded in the entirety of its DNA sequence, what’s on DNA and how it's packaged are increasingly important for understanding disease, including cancer. This second webinar in The Scientist's Decoding DNA series will cover the Secrets of the Epigenome, discussing what is currently known about DNA methylation, histone modifications, and chromatin remodeling and how this knowledge can translate to useful therapies. Following brief presentations by our panel of experts, there will be a live Q&A session during which attendees can ask questions and discuss issues related to the burgeoning field of epigenetics.
DNA Methylation Abnormalities in Cancer: Biological and Translational Implications
Stephen Baylin is a professor of medicine and of oncology at the Johns Hopkins University School of Medicine, where he is also Chief of the Cancer Biology Division of the Oncology Center and Associate Director for Research of The Sidney Kimmel Comprehensive Cancer Center. Together with Peter Jones, Baylin also leads the Epigenetic Therapy Stand up to Cancer Team (SU2C). He and his colleagues have fostered the concept that DNA hypermethylation of gene promoters, with its associated transcriptional silencing, can serve as alternatives to mutations for producing loss of tumor-suppressor gene function. Baylin earned both his BS and MD degrees from Duke University, where he completed his internship and first-year residency in internal medicine. He then spent 2 years at the National Heart and Lung Institute of the National Institutes of Health. In 1971, he joined the departments of Oncology and Medicine at the Johns Hopkins University School of Medicine, an affiliation that still continues.
Targeting Chromatin-Modifying Enzymes in Cancer Therapy
Victoria Richon heads the Drug Discovery and Preclinical Development Global Oncology Division at Sanofi. Richon joined Sanofi in November 2012 from Epizyme, where she was Vice President of Biological Sciences since 2008. There she was responsible for the strategy and execution of drug discovery and development efforts that ranged from target identification through candidate selection and clinical development, including biomarker strategy and execution. Richon received her BA in chemistry from the University of Vermont and her PhD in biochemistry from the University of Nebraska. She completed her postdoctoral research at Memorial Sloan-Kettering Cancer Center.
When Metabolism and Epigenetics Converge
Paolo Sassone-Corsi is Donald Bren Professor of Biological Chemistry and Director of the Center for Epigenetics and Metabolism at the University of California, Irvine, School of Medicine. Sassone-Corsi is a molecular and cell biologist who has pioneered the links between cell-signaling pathways and the control of gene expression. His research on transcriptional regulation has elucidated a remarkable variety of molecular mechanisms relevant to the fields of endocrinology, neuroscience, metabolism, and cancer. He received his PhD from the University of Naples and completed his postdoctoral research at CNRS, Strasbourg, France.
Click here to register now!
Not able to attend? Forward information on this webinar to your colleagues.
If you wish to unsubscribe from this mailing please click here .
free webinar
t
From: The Scientist Magazine
Sent: Monday, April 08, 2013 10:36 AM
To: tamarque@earthlink.net
Subject: Upcoming Webinar: Unraveling the Secrets of the Epigenome
Unraveling the Secrets of the Epigenome
________________________________
FREE Webinar — Thursday April 18, 2013
2:30-4:00 p.m. Eastern Time
Click here to register now!
While the human genome continues to intrigue researchers with the complexities embedded in the entirety of its DNA sequence, what’s on DNA and how it's packaged are increasingly important for understanding disease, including cancer. This second webinar in The Scientist's Decoding DNA series will cover the Secrets of the Epigenome, discussing what is currently known about DNA methylation, histone modifications, and chromatin remodeling and how this knowledge can translate to useful therapies. Following brief presentations by our panel of experts, there will be a live Q&A session during which attendees can ask questions and discuss issues related to the burgeoning field of epigenetics.
DNA Methylation Abnormalities in Cancer: Biological and Translational Implications
Stephen Baylin is a professor of medicine and of oncology at the Johns Hopkins University School of Medicine, where he is also Chief of the Cancer Biology Division of the Oncology Center and Associate Director for Research of The Sidney Kimmel Comprehensive Cancer Center. Together with Peter Jones, Baylin also leads the Epigenetic Therapy Stand up to Cancer Team (SU2C). He and his colleagues have fostered the concept that DNA hypermethylation of gene promoters, with its associated transcriptional silencing, can serve as alternatives to mutations for producing loss of tumor-suppressor gene function. Baylin earned both his BS and MD degrees from Duke University, where he completed his internship and first-year residency in internal medicine. He then spent 2 years at the National Heart and Lung Institute of the National Institutes of Health. In 1971, he joined the departments of Oncology and Medicine at the Johns Hopkins University School of Medicine, an affiliation that still continues.
Targeting Chromatin-Modifying Enzymes in Cancer Therapy
Victoria Richon heads the Drug Discovery and Preclinical Development Global Oncology Division at Sanofi. Richon joined Sanofi in November 2012 from Epizyme, where she was Vice President of Biological Sciences since 2008. There she was responsible for the strategy and execution of drug discovery and development efforts that ranged from target identification through candidate selection and clinical development, including biomarker strategy and execution. Richon received her BA in chemistry from the University of Vermont and her PhD in biochemistry from the University of Nebraska. She completed her postdoctoral research at Memorial Sloan-Kettering Cancer Center.
When Metabolism and Epigenetics Converge
Paolo Sassone-Corsi is Donald Bren Professor of Biological Chemistry and Director of the Center for Epigenetics and Metabolism at the University of California, Irvine, School of Medicine. Sassone-Corsi is a molecular and cell biologist who has pioneered the links between cell-signaling pathways and the control of gene expression. His research on transcriptional regulation has elucidated a remarkable variety of molecular mechanisms relevant to the fields of endocrinology, neuroscience, metabolism, and cancer. He received his PhD from the University of Naples and completed his postdoctoral research at CNRS, Strasbourg, France.
Click here to register now!
Not able to attend? Forward information on this webinar to your colleagues.
If you wish to unsubscribe from this mailing please click here .